|
Post by peppy on Aug 5, 2021 16:10:56 GMT -5
Who, who came in at the End of Trading? Driving SP up to $4.20. It was not The WHO. It was Fauci. Fauci had a presentation 4/23/21..... The 16 min mark. www.youtube.com/watch?v=SrEwCeoi7uA
|
|
|
Post by lazyb767 on Aug 5, 2021 16:46:28 GMT -5
Who, who came in at the End of Trading? Driving SP up to $4.20. It was not The WHO. It was Fauci. Fauci had a presentation 4/23/21..... The 16 min mark. www.youtube.com/watch?v=SrEwCeoi7uANot making the connection, could be my after lunch slump. How does this video, dated 4/23, correlate with the end of day trading? I started the video at the 16 min mark.
|
|
|
Post by mytakeonit on Aug 5, 2021 16:49:05 GMT -5
You went looking ... so I guess you Got Fooled Again.
In any case, it wasn't me because I got a few more shares at $4.11
But, that's mytakeonit
|
|
|
Post by peppy on Aug 5, 2021 17:15:39 GMT -5
You went looking ... so I guess you Got Fooled Again. In any case, it wasn't me because I got a few more shares at $4.11 But, that's mytakeonit IF, big IF, MannKind can pull off an inhaled version of Zyesami, to the MOON. That is a take on this. ******************************************************************************** NRx and MannKind to develop Zyesami inhaler for respiratory ailments www.pharmaceutical-technology.com/news/nrx-mannkind-zyesami-inhaler/05 Aug 2021 (Last Updated August 5th, 2021 12:39) MannKind will evaluate the potential of the inhaled drug formulation at its Danbury plant in the US. NRx Pharmaceuticals has entered an agreement with MannKind to create a dry powder formulation of its investigational drug, Zyesami (aviptadil), for the treatment of various respiratory ailments. Zyesami is a synthetic form of human vasoactive intestinal peptide (VIP), an endogenous substance made by the body to provide protection to cells against inflammatory conditions. The alliance will leverage MannKind’s Technosphere platform to develop the inhaler product. A US Food and Drug Administration (FDA)-approved inhaled insulin product, Afrezza, is based on the Technosphere platform, NRx noted. Furthermore, MannKind will assess the potential of the inhaled formulation at its research and manufacturing plant in Danbury, Connecticut, US. The Danbury site has vast development and manufacturing expertise such as analytical, chemical, formulation, filling and packaging capabilities. In addition, the facility has an adequate filling capacity to manufacture more than 300 million cartridges of inhaled drugs a year. MannKind CEO Michael Castagna said: “We are looking forward to the collaboration with NRx and looking for an avenue to marry the benefits of our Technosphere technology with Zyesami. **************************************************************************************************************************** It keeps getting better. Volume Ten may be another Moon Shot. Oh please.
|
|
|
Post by dh4mizzou on Aug 5, 2021 17:30:23 GMT -5
Peppy
Thanks for posting. But I am a little concerned with the word "investigational" being associated with the drug.
That tells me we could have a long wait for anything fruitful to happen.
|
|
|
Post by dh4mizzou on Aug 5, 2021 17:30:47 GMT -5
Peppy
Thanks for posting. But I am a little concerned with the word "investigational" being associated with the drug.
That tells me we could have a long wait for anything fruitful to happen.
|
|
|
Post by cretin11 on Aug 5, 2021 17:42:33 GMT -5
You can do it Little Bob....sell, sell, sell!! A little tougher to control today, eh? Maybe you’re right! Oops, never mind, share price down 20% over the past month. Your imaginary buddy Bob doesn’t seem to be sweating much. But we MNKD longs need to celebrate the good days, even if only up a few pennies, so this calls for opening a bottle of wine!
|
|
|
Post by peppy on Aug 5, 2021 17:44:28 GMT -5
Peppy Thanks for posting. But I am a little concerned with the word "investigational" being associated with the drug. That tells me we could have a long wait for anything fruitful to happen. Fauci quote, "3 new clinal trials being started this week." ************************************************************************************************************************************* Intravenous Aviptadil for Critical COVID-19 With Respiratory Failure (COVID-AIV) clinicaltrials.gov/ct2/show/NCT04311697ClinicalTrials.gov Identifier: NCT04311697 Recruitment Status : Completed First Posted : March 17, 2020 Last Update Posted : February 26, 2021 Sponsor: NeuroRx, Inc. ***************************************************************************************************** All help from the team and most opinions appreciated.
|
|
|
Post by cjm18 on Aug 5, 2021 21:10:43 GMT -5
Looks like we will run up to earnings.
|
|
|
Post by cedafuntennis on Aug 5, 2021 22:00:35 GMT -5
Isn't Zyesami the drug MNKD just partnered for with NRx Pharma? Also, MNKD has patents covering VIP (Vasoactive Intestinal Peptide) with TA. Make the link now?
|
|
|
Post by peppy on Aug 5, 2021 22:09:06 GMT -5
|
|
|
Post by peppy on Aug 6, 2021 9:31:29 GMT -5
MNKD Volume at 1 hour of trade, real time, 280,589 summary, 469,524 Avg. Volume 3,389,935
4.0250. -0.1750 (-4.1667%) As of 10:30AM EDT. Market open.
added, MNKD Volume at 2 hours of trade. real time, 418,708 summary, 750,488
$4.0271. -0.1729 (-4.1167%)
|
|
|
Post by peppy on Aug 6, 2021 11:46:18 GMT -5
MNKD Volume at 1 hour of trade, real time, 280,589 summary, 469,524 Avg. Volume 3,389,935 4.0250. -0.1750 (-4.1667%) As of 10:30AM EDT. Market open. added, MNKD Volume at 2 hours of trade. real time, 418,708 summary, 750,488 $4.0271. -0.1729 (-4.1167%) MNKD Volume at the half day of trade. real time, 489,133 shares. summary, 914,973 shares. $4.0150. -0.1850 (-4.4048%) As of 12:45PM EDT. Market open.
|
|
|
Post by peppy on Aug 6, 2021 15:09:03 GMT -5
MNKD Volume at 1 hour of trade, real time, 280,589 summary, 469,524 Avg. Volume 3,389,935 4.0250. -0.1750 (-4.1667%) As of 10:30AM EDT. Market open. added, MNKD Volume at 2 hours of trade. real time, 418,708 summary, 750,488 $4.0271. -0.1729 (-4.1167%) MNKD Volume at the half day of trade. real time, 489,133 shares. summary, 914,973 shares. $4.0150. -0.1850 (-4.4048%) As of 12:45PM EDT. Market open. MNKD Nasdaq real time volume, 1,767,061 shares. (A million shares came in the last few mins.) MNKD Nasdaq summary volume, 1,954,950 shares. $4.04. -0.16. (-3.81%) At close: 4:00PM EDT www.nasdaq.com/market-activity/stocks/mnkd/latest-real-time-tradesfinance.yahoo.com/quote/MNKD?p=MNKD
|
|
|
Post by peppy on Aug 9, 2021 6:31:50 GMT -5
MNKD Volume at the half day of trade. real time, 489,133 shares. summary, 914,973 shares. $4.0150. -0.1850 (-4.4048%) As of 12:45PM EDT. Market open. MNKD Nasdaq real time volume, 1,767,061 shares. (A million shares came in the last few mins.) MNKD Nasdaq summary volume, 1,954,950 shares. $4.04. -0.16. (-3.81%) At close: 4:00PM EDT www.nasdaq.com/market-activity/stocks/mnkd/latest-real-time-tradesfinance.yahoo.com/quote/MNKD?p=MNKDreal time volume on Friday changed, from, 1,767,061 shares to 2,368,903 shares.
It keeps happening.
|
|